Drug Approval | February 27, 2025
USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit
The observations issued are neither repeated observations nor related to data integrity
The observations issued are neither repeated observations nor related to data integrity
The project is set to attract significant manufacturing investments of approximately Rs. 10,500 crore and is also projected to create around 1 lakh direct and indirect jobs
The inspection conducted by EDQM at its Visakhapatnam facility
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Laurus Labs receives EIR from USFDA for API facilities
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Lupin enters into BTA with Lupin Manufacturing Solutions
Mankind Pharma commences the commercial operations newly set-up plant in Udaipur
AHH will make an investment of Rs. 600 crore in the company through a mix of primary and secondary infusion
Subscribe To Our Newsletter & Stay Updated
